



FP7 Cooperation Work Programme: Health-2011 Topics and contact points

Date of publication: 30 July 2010

Call identifiers:	Indicative budgets	Deadlines
FP7-HEALTH-2011-single-stage	EUR 160.5 million	10 November 2010 (TBC)
FP7-HEALTH-2011-two-stage	EUR 498 million	13 October 2010 (TBC) (for stage 1 proposals)
FP7-ERANET-2011-RTD	EUR 4 million	22 February 2011 (TBC)
TOTAL	EUR 662.5 million	(TBC)

Funding schemes:

CP-FP (Collaborative Project-Small or medium-scale Focused research project);
CP-IP (Collaborative Project-Large scale Integrating Project); NoE (Network of Excellence)
CA (Coordination and Support Action - Coordinating Action)
SA (Coordination and Support Action - Supporting Action)

1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

1.1 HIGH-THROUGHPUT RESEARCH

HEALTH-2011-TWO-STAGE

- **1.1-1: SME-targeted research for developing tools and technologies for high-throughput research**
SME CP-FP, max € 6m (1 or more projects)
Scientific officers: **Tomasz DYLAG** (tomasz.dylag@ec.europa.eu), **Iiro EEROLA** (iiro.eerola@ec.europa.eu) (UNIT F.4)
- **1.1-2: Genome-based biomarkers for patient stratification and pharmacogenomic strategies**
SME CP-FP, max € 6m (1 or more projects)
Scientific officer: **Fergal DONNELLY** (fergal.donnelly@ec.europa.eu) (UNIT F.4)

FP7-HEALTH-2011-SINGLE-STAGE

- **1.1-3: High-throughput proteomics for human health and disease**
CP-FP, max € 3m (1 or more projects)
Scientific officer: **Tomasz DYLAG** (tomasz.dylag@ec.europa.eu) – (UNIT F.4)

1.2 DETECTION, DIAGNOSIS AND MONITORING

Closed in WP 2011

1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES

Closed in WP 2011

1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS

FP7-HEALTH-2011-TWO-STAGE

- **1.4-1: Regenerative medicine clinical trials** - CP-FP, max € 6m (1 or more projects)
Scientific Officers: **Charles KESSLER** (Charles.Kessler@ec.europa.eu); **David GANCBERG** (David.Gancberg@ec.europa.eu) (UNIT F.5)

- **1.4-2: Tools, technologies and devices for application in regenerative medicine**
SME CP-FP, max € 6m (1 or more projects)
Scientific Officers: [Charles KESSLER](mailto:Charles.Kessler@ec.europa.eu) (Charles.Kessler@ec.europa.eu); [Bernd RAINER](mailto:Bernd-Walter.Rainer@ec.europa.eu) (Bernd-Walter.Rainer@ec.europa.eu); [Torbjoern INGEMANSSON](mailto:Torbjoern.Ingemansson@ec.europa.eu) (Torbjoern.Ingemansson@ec.europa.eu) – (UNIT F.5)
 - **1.4-3: Development and production of new, high-affinity protein scaffolds for therapeutic use**
SME CP-FP, max € 6m (1 or more projects)
Scientific Officer: [Juergen SAUTTER](mailto:Juergen.Sautter@ec.europa.eu) (Juergen.Sautter@ec.europa.eu) – (UNIT F.5)
- FP7-HEALTH-2011-SINGLE-STAGE**
- **1.4-4: High impact initiative for better immunisation** - CP-IP, max € 30m (max 1 project)
Scientific Officer: [Andreas HOLTEL](mailto:Andreas.Holtel@ec.europa.eu) (Andreas.Holtel@ec.europa.eu) – (UNIT F.5)
 - **1.4-5: New therapeutic approaches in chronic inflammatory and autoimmune diseases**
CP-FP, max € 3m (1 or more projects)
Scientific Officers: [Charles KESSLER](mailto:Charles.Kessler@ec.europa.eu) (Charles.Kessler@ec.europa.eu); [Arnd HOEVELER](mailto:Arnd.Hoeverler@ec.europa.eu) (Arnd.Hoeverler@ec.europa.eu) (UNIT F.5)

2. TRANSLATING RESEARCH FOR HUMAN HEALTH

2.1 INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY

- **2.1-1: Large-scale data gathering**
 - **2.1.1-1: High impact initiative on the human epigenome** - CP-IP, max € 30m (max 1 project)
FP7-HEALTH-2011-SINGLE-STAGE
Scientific officer: [Jacques REMACLE](mailto:jacques.remacle@ec.europa.eu) (jacques.remacle@ec.europa.eu) (UNIT F.4)
 - **2.1.1-2: Proteins and their interactions in health and disease** – CP-IP, max € 12m (1 or more projects)
FP7-HEALTH-2011-TWO-STAGE
Scientific officer: [Tomasz DYLAG](mailto:tomasz.dylag@ec.europa.eu) (tomasz.dylag@ec.europa.eu) (UNIT F.4)
 - **2.1.1-3: Large-scale genomics approaches to identify host determinants of infectious diseases**
CP-IP, max € 12m (max 1 project)
FP7-HEALTH-2011-TWO-STAGE
 - **2.1.1-4: Population genetics studies on cardio-metabolic disorders in EU/AC and EECA populations**
SICA CP-FP, max € 6m (max 1 project)
FP7-HEALTH-2011-SINGLE-STAGE
Scientific officer: [Iiro EEROLA](mailto:iiro.eerola@ec.europa.eu) (iiro.eerola@ec.europa.eu) (UNIT F.4)
- **2.1-2: Systems biology**
Closed in WP 2011

2.2 RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING

- **2.2-1: Brain and brain-related diseases**
 - **2.2.1-1: Investigator-driven clinical trials for childhood-onset neurodegenerative diseases**
CP-FP, max € 6m (1 or more projects) - **FP7-HEALTH-2011-TWO-STAGE**
Scientific officer: [Elmar NIMMESGERN](mailto:elmar.nimmesgern@ec.europa.eu) (elmar.nimmesgern@ec.europa.eu) – (UNIT F.2)
 - **2.2.1-2: Understanding the role of neuroinflammation in neurodegenerative diseases** - CP-IP, max € 12m (1 or more project)
FP7-HEALTH-2011-TWO-STAGE
 - **2.2.1-3: Addictive and/or compulsive behaviour in children and adolescents: translating pre-clinical results into therapies** - CP-FP, max € 6m (1 or more projects) - **FP7-HEALTH-2011-TWO-STAGE**
Scientific officer: [Patrizia TOSETTI](mailto:patrizia.tosetti@ec.europa.eu) (patrizia.tosetti@ec.europa.eu) – (UNIT F.2)
 - **2.2.1-4: Creating clinical and molecular tools for experimental therapy of paediatric neurodegenerative disorders causing childhood dementia in Europe and India** - CP-FP, max € 3m (1 or more projects) - **FP7-HEALTH-2011-SINGLE-STAGE**
Scientific officer: [Elmar NIMMESGERN](mailto:elmar.nimmesgern@ec.europa.eu) (elmar.nimmesgern@ec.europa.eu) – (UNIT F.2)
 - **2.2.1-5: ERA-Net on disease-related neurosciences** - CA, max € 2m (max 1 project) - **FP7-ERANET-2011-RTD**
Scientific officer: [Patrizia TOSETTI](mailto:patrizia.tosetti@ec.europa.eu) (patrizia.tosetti@ec.europa.eu) – (UNIT F.2)

- **2.2-2: Human Development and ageing**

FP7-HEALTH-2011-TWO-STAGE

2.2.2-1: Investigator-driven clinical trials for therapeutic interventions in the elderly populations
CP-FP, max € 6m (1 or more projects)

2.2.2-2: Linking human development and ageing - CP-FP, max € 3m (1 or more projects)

Scientific officer: [Beatrice LUCARONI](mailto:Beatrice.lucaroni@ec.europa.eu) (Beatrice.lucaroni@ec.europa.eu) – (UNIT F.2)

2.3 TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

- **2.3-1: Anti-microbial drug resistance**

2.3.1-1: Investigator-driven clinical trials of off-patent antibiotics - CP-FP, max € 6m (1 or more projects)

FP7-HEALTH-2011-TWO-STAGE

2.3.1-2: Multi-disciplinary research on the evolution and transfer of antibiotic resistance - CP-IP, max € 12m (max 1 project)

FP7-HEALTH-2011-SINGLE-STAGE

2.3.1-3: Management of Gram negative multi-drug resistant infections - CP-IP, max € 12m (max 1 project)

FP7-HEALTH-2011-SINGLE-STAGE

2.3.1-4: Development of multi-analyte diagnostic tests – SME CP-FP, max € 3m (1 or more projects)

FP7-HEALTH-2011-TWO-STAGE

2.3.1-5: Development of tools to control microbial biofilms with relevance to clinical drug resistance

SME CP-FP, max € 3m (1 or more projects) - **FP7-HEALTH-2011-TWO-STAGE**

Scientific officer: [Arjon VAN HENGEL](mailto:adrianus.van-hengel@ec.europa.eu) (adrianus.van-hengel@ec.europa.eu) – (UNIT F. 3)

- **2.3-2: HIV/AIDS, malaria and tuberculosis**
Closed in WP 2011

- **2.3-3: Potentially new and re-emerging epidemics**

2.3.3-1: Identification of factors promoting the emergence of pathogens with human pandemic potential from pathogens with a zoonotic background and related prevention strategies - CP-IP, max € 12m (max 1 project)

FP7-HEALTH-2011-TWO-STAGE

2.3.3-2: Comprehensive control of Dengue fever under changing climatic conditions

SICA CP-FP, max € 6m (1 or more projects) - **FP7-HEALTH-2011-SINGLE-STAGE**

2.3.3-3: Development of an evidence-based behavioural and communication package to respond to major epidemic outbreaks - CP-FP, max € 2m (1 or more projects) - **FP7-HEALTH-2011-TWO-STAGE**

Scientific officer: [Christian DESAINTEs](mailto:Christian.desaintes@ec.europa.eu) (Christian.desaintes@ec.europa.eu) – (UNIT F.3)

- **2.3-4: Neglected infectious diseases**
Closed in WP 2011

2.4 TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

- **2.4-1: Cancer**

2.4.1-1: Investigator-driven, treatment trials for rare cancers – CP-FP, max € 6m (1 or more projects)

FP7-HEALTH-2011-TWO STAGE

Scientific officer: [Dominika TRZASKA](mailto:dominika.trzaska@ec.europa.eu) (dominika.trzaska@ec.europa.eu) – (UNIT F.2)

2.4.1-2: Translational research on cancers with poor prognosis – CP-FP, max € 3m (1 or more projects)

FP7-HEALTH-2011-TWO STAGE

Scientific officer: [Jan VAN DE LOO](mailto:jan-willem.van-de-loo@ec.europa.eu) (jan-willem.van-de-loo@ec.europa.eu) – (UNIT F.2)

2.4.1-3: Epidemiology and aetiology of infection-related cancers – CP-FP, max € 3m (1 or more projects)

FP7-HEALTH-2011-SINGLE-STAGE

Scientific officer: [Flemming NIELSEN](mailto:flemming.nielsen@ec.europa.eu) (flemming.nielsen@ec.europa.eu) – (UNIT F.2)

- **2.4-2: Cardiovascular diseases - FP7-HEALTH-2010-TWO-STAGE**

2.4.2-1: Investigator-driven clinical trials for the management of cardiovascular diseases

CP-IP, max € 12m (1 or more projects)

2.4.2-2: Evaluation and validation studies of clinically useful biomarkers in prevention and management of cardiovascular diseases – SME CP-FP, max € 6m (1 or more projects)

Scientific officer: **Virginija DAMBRAUSKAITE** (virginija.dambrauskaite@ec.europa.eu); **(UNIT F.2)**

- **2.4-3: Diabetes and obesity - - FP7-HEALTH-2010-TWO-STAGE**

2.4.3-1: Investigator-driven clinical trials to reduce diabetes complications – CP-FP, max € 6m (1 or more projects)

2.4.3-2: Development of novel treatment strategies based on knowledge of cellular dysfunction

CP-FP, max € 6m (1 or more projects)

2.4.3-3: Molecular and physiological effects or lifestyle factors on diabetes/obesity – CP-FP, max € 6m (1 or more projects)

2.4.3-4: Genetic and environmental factors in obesity and/or diabetes in specific populations

SICA CP-FP, max € 3m (1 or more projects)

FP7-ERANET-2011-RTD

2.4.3-5: ERA-NET on diabetes prevention and treatment - CA, max € 2m (max 1 project)

Scientific officer: **Nathalie VERCRUYSE** (nathalie.vercruyse@ec.europa.eu) – **(UNIT F.2)**

- **2.4-4: Rare diseases**

Closed in WP 2011

- **2.4-5: Other chronic diseases**

Closed in WP 2011

3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS

3.1 TRANSLATING CLINICAL RESEARCH INTO PRACTICE

Closed in WP 2011

3.2 QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS

Closed in WP 2011

3.3 HEALTH PROMOTION

FP7-HEALTH-2011-TWO-STAGE

- **3.3-1: Developing methodologies to reduce inequities in the determinants of health**

CP-FP, max € 3m (1 or more projects)

Scientific officer: **Kevin McCARTHY** (kevin.mccarthy@ec.europa.eu) - **(UNIT F.3.01)**

- **3.3-2: Analysis of integrated strategies for sustainable behaviour change**

CP-FP, max € 3m (1 or more projects)

Scientific officer: **Jan PAEHLER** (jan.paehler@ec.europa.eu) - **(UNIT F.3.01)**

FP7-HEALTH-2011-SINGLE-STAGE

- **3.3-3: Developing and implementing methods for the transfer of research into policy in the fields of health promotion and disease prevention - CP-FP, max € 3m (max 1 project)**

Scientific officer: **Kevin McCARTHY** (kevin.mccarthy@ec.europa.eu) - **(UNIT F.3.01)**

- **3.3-4: A road-map for mental health research in Europe - CA, max € 2m (max 1 project)**

Scientific officer: **Jan PAEHLER** (jan.paehler@ec.europa.eu) - **(UNIT F.3.01)**

FP7-HEALTH-2010-SINGLE-STAGE

- **3.4-1: Develop and assessment of comprehensive and integrated interventions and programmes to improve reproductive health and health equity** - SICA CP-FP, max € 3m (1 or more projects)
Scientific officer: **Jan PAEHLER** (jan.paehler@ec.europa.eu) - **(UNIT F.3.01)**
- **3.4-2: Building sustainable capacity for research for health and its social determinants in low & middle income countries** - CA, max € 2m (1 or more projects)
Scientific officer: **Kevin McCARTHY** (kevin.mccarthy@ec.europa.eu) - **(UNIT F.3.01)**
- **3.4-3: Multilateral cooperation between Europe, Africa and Latin America on public health and health services research** – CA, max € 2m (max 1 project)
Scientific officer: **Kevin McCARTHY** (kevin.mccarthy@ec.europa.eu) - **(UNIT F.3.01)**

4. OTHER ACTIONS ACROSS THE HEALTH THEME

4.1 COORDINATION & SUPPORT ACTIONS ACROSS THE THEME

FP7-HEALTH-2010-SINGLE-STAGE

- **4.1-1: Networking of major research institutions to coordinate communication actions aimed at the media and the general public** - CA, max € 2m (max 1 project)
Scientific officer: **Josefina ENFEDAQUE** (josefina.enfedaque@ec.europa.eu) - **(UNIT F.1)**
- **4.1-2: Targeting publication bias** - SA, max € 500.000 (1 or more projects)
Scientific officer: **Joana NAMORADO** (joana.namorado@ec.europa.eu) - **(UNIT F.1)**
- **4.1-3: Linking EU and Latin American policy making institutions in the field of health research**
CA, max € 2m (max 1 project)
Scientific officer: **Indridi BENEDIKTSSON** (indridi.benediktsson@ec.europa.eu) - **(UNIT F.1)**
- **4.1-4: Organisation of supporting actions and events related to the Presidency of the European Union**
SA, max € 100.000 m (1 or more projects)
Scientific officer: **Josefina ENFEDAQUE** (josefina.enfedaque@ec.europa.eu) - **(UNIT F.1)**

4.2 RESPONDING TO EU POLICY NEEDS

FP7-HEALTH-2010-SINGLE-STAGE

- **4.2-1: Investigator-driven clinical trials on off-patent medicines for children** - CP-FP, max € 6m (1 or more projects)
 - **4.2-2: Adverse drug reaction research** – CP-FP, max € 3m (1 or more projects)
 - **4.2-3: New methodologies for clinical trials in personalised medicine** – SME CP-FP, max € 3m (1 or more projects)
- Scientific officer:** **Fergal DONNELLY** (fergal.donnelly@ec.europa.eu) - **(UNIT F.4)**